)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Chemomab Therapeutics
Chemomab Therapeutics (CCMB) investor relations material
Chemomab Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary14 May, 2026
Executive summary
Presented new clinical and translational data at major medical meetings, confirming nebokitug's disease-modifying potential in PSC and suggesting added benefit for patients with co-existing IBD.
Advanced multiple partnering discussions for nebokitug, with ongoing strategic evaluations.
Financial highlights
Cash, cash equivalents, and short-term bank deposits totaled $8.0 million as of March 31, 2026, expected to fund operations through Q1 2027.
R&D expenses were $0.9 million in Q1 2026, down from $2.5 million in Q1 2025, reflecting the wind-down of the Phase 2 SPRING trial.
G&A expenses were $0.9 million in Q1 2026, compared to $1.0 million in Q1 2025.
Net loss for Q1 2026 was $1.8 million, or less than $0.01 per share, compared to $3.3 million in Q1 2025.
576,030,200 ordinary shares issued and outstanding as of March 31, 2026.
Outlook and guidance
Existing liquidity is expected to support operations through the end of Q1 2027.
Continued focus on advancing nebokitug through strategic partnerships and further clinical development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chemomab Therapeutics
- Nebokitug demonstrated robust Phase 2 efficacy and safety in PSC, advancing to Phase 3 with first-to-market potential.CCMB
Corporate presentation20 Mar 2026 - FDA-aligned Phase 3 path for nebokitug in PSC, improved financials, and strong clinical data.CCMBQ4 202519 Mar 2026
- Nebokitug advances to phase III in PSC after strong phase II results, targeting major unmet needs.CCMBOppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026
- CM-101 showed strong safety and efficacy in Phase 2 PSC, supporting advancement to Phase 3.CCMBStudy Result3 Feb 2026
- CM-101 showed strong Phase II results in PSC and is advancing to a global Phase III trial.CCMBOppenheimer 35th Annual Healthcare Life Sciences Conference 202524 Dec 2025
- Registering 8.1M ADSs for resale after $10M financing to fund rare disease antibody development.CCMBRegistration Filing16 Dec 2025
- Regulatory and clinical milestones position nebokitug for a pivotal Phase 3 PSC trial.CCMBQ3 202521 Nov 2025
- Nebokitug's phase II success in PSC paves the way for a pivotal phase III and potential first approval.CCMBH.C. Wainwright 27th Annual Global Investment Conference20 Oct 2025
- Phase 3 prep for nebokitug in PSC advances, with strong data, new patents, and cash runway to 2026.CCMBQ2 202512 Sep 2025
Next Chemomab Therapeutics earnings date
Q2 202613 Aug, 2026
Chemomab Therapeutics
Next Chemomab Therapeutics earnings date
Q2 202613 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage